We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Norfolk Southern Corporation (NSC - Free Report) reported first-quarter 2018 earnings per share of $1.93, beating the Zacks Consensus Estimate of $1.77. Earnings increased 30.4% on a year-over-year basis.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Norfolk Southern depicted a gloomy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 2.2% downward over the last 30 days.
However, Norfolk Southern has an impressive earnings surprise history. The company delivered positive surprises in each of the past four quarters with an average beat of 7.2%.
Revenues Better Than Expected
Norfolk Southern recorded railway operating revenues of $2,717 billion, which surpassed the Zacks Consensus Estimate of $2,681.8 million. Moreover, it increased 5.5% year over year.
Norfolk Southern Corporation Price and EPS Surprise
Key Q1 Statistics: Norfolk Southern revealed that operating ratio (operating expenses as a percentage of revenues) in the reported quarter was a record 69.3%. Overall volumes grew 3% on the back of impressive performance at the intermodal segment.
Check back later for our full write up on this Norfolk Southern earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Norfolk Southern (NSC) Beats on Q1 Earnings
Norfolk Southern Corporation (NSC - Free Report) reported first-quarter 2018 earnings per share of $1.93, beating the Zacks Consensus Estimate of $1.77. Earnings increased 30.4% on a year-over-year basis.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for Norfolk Southern depicted a gloomy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 2.2% downward over the last 30 days.
However, Norfolk Southern has an impressive earnings surprise history. The company delivered positive surprises in each of the past four quarters with an average beat of 7.2%.
Revenues Better Than Expected
Norfolk Southern recorded railway operating revenues of $2,717 billion, which surpassed the Zacks Consensus Estimate of $2,681.8 million. Moreover, it increased 5.5% year over year.
Norfolk Southern Corporation Price and EPS Surprise
Norfolk Southern Corporation Price and EPS Surprise | Norfolk Southern Corporation Quote
Key Q1 Statistics: Norfolk Southern revealed that operating ratio (operating expenses as a percentage of revenues) in the reported quarter was a record 69.3%. Overall volumes grew 3% on the back of impressive performance at the intermodal segment.
Zacks Rank: Currently, Norfolk Southern carries a Zacks Rank #3 (Hold) which is subject to change following the earnings announcement. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Norfolk Southern earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>